関連する実験動画
Updated: Sep 9, 2025
08:16
One-anastomosis Gastric Bypass OAGB in Rats
Published on: November 10, 2018
11.0K
胃バイパスの後の体重減少は,肥満の患者における正体性ストレスに対するアルドステロンの反応性を高めます
Joachim Zahnd1, Nima Vakilzadeh1, Nora Schwotzer1
1Service of nephrology and hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Blood pressure
|September 2, 2025
まとめ
減量手術 (RYGB) は ストレスに対するアルドステロンとナトリウム反応を高めます この研究は,Roux-en-Y 胃バイパスが 矯正手術中に体内のホルモンと腎臓のシステムにどのように影響するかを明らかにしています.
科学分野:
- 内分泌学
- 腎臓科
- 腹部 外科
背景:
- 胃バイパス手術後の体重減少は,血圧の低下と関連しています.
- この血圧低下における共感神経系とレニン・アニオテンシン・アルドステロン系の特定の役割は完全に理解されていません.
研究 の 目的:
- Roux-en-Y胃バイパス (RYGB) で達成された体重減少が,静止性ストレスに対する血液動力学,ホルモン,腎臓の反応に与える影響を調査する.
- RYGB後の血圧調節におけるレニン・アニオテンシン・アルドステロン系の関与を明らかにする.
主な方法:
- RYGB治療を受けた肥満患者とライフスタイルカウンセリングを受けた患者 (対照群) を比較した単一中心研究が行われました.
- 低体負圧 (LBNP) を使って正体圧を誘導した.
- 尿中のナトリウム分泌量,血液動力学,ホルモン反応は,LBNP前,中,後,介入後3ヶ月で測定された.
主要な成果:
- RYGBグループは,対照群 (126. 3kgから116kg) と比較して,12ヶ月で著しい体重減少 (p < 0. 01) を経験した.
- LBNPでは,RYGB群は尿中のナトリウム排出量がより顕著に減少した (-1. 98 mmol/ h; p=0. 02) と,血アルドステロン濃度がより大きく増加した (+ 9. 94 pg/ ml; p=0. 043).
結論:
- RYGBによって誘発された体重減少は,アルドステロンの正体性ストレスへの反応性を高めます.
- RYGBは,静止性ストレス中に改善されたナトリウム管反応を促進し,血圧の調節に潜在的に貢献します.
関連する概念動画
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
751
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
751
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:17Antihypertensive Drugs: Action of β1 Blockers
609
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
609
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
911
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911